Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001972740 | SCV002245640 | pathogenic | Spastic paraplegia | 2021-11-06 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the SACS protein in which other variant(s) (p.Tyr4538*) have been determined to be pathogenic (Invitae). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. This variant has not been reported in the literature in individuals affected with SACS-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Glu2418*) in the SACS gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 2162 amino acid(s) of the SACS protein. |
Baylor Genetics | RCV003475241 | SCV004202319 | likely pathogenic | Charlevoix-Saguenay spastic ataxia | 2021-12-21 | criteria provided, single submitter | clinical testing |